Press & Nyheter

ViewReleaseInStandardHtml

Bulletin from Annual General Meeting in Boule Diagnostics AB on May 6, 2019

The Annual General Meeting (the ”AGM”) decided to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2018. Furthermore, it was decided that a dividend of  SEK 0.55 per share will be distributed and remaining profit shall be carried forward.

The AGM also decided to discharge the board members and the CEO from liability for 2018.

The AGM approved the nominating committee’s proposal that the board shall consist of five board members without deputies.

The AGM decided that the remuneration to the chairman of the board shall amount to SEK 470,000 (450,000 for 2018) and that the remuneration to the other board members shall be SEK 235,000 (225,000 for 2018) each. The entirety of the board is expected to fulfill the duties of the audit and remuneration committees, and no additional remuneration is proposed for committee work. The total remuneration to the board is hence amounted to SEK 1,410,000 (1,350,000 for 2018).

The AGM also decided that the remuneration to the auditor, as previous, will be on specified current account.

The AGM decided that the board until the end of the next Annual General Meeting will consist of the members Karin Dahllöf, Peter Ehrenheim, Thomas Eklund, Charlotta Falvin and Jon Risfelt through re-election. Peter Ehrenheim was re-elected chairman of the board.

Öhrlings PriceWaterhouseCoopers AB was re-elected as the company’s auditor, with Leonard Daun as auditor in charge, until the end of the Annual General Meeting of 2020.

The AGM approved the proposed instructions for the nomination committee.

The AGM approved the board’s proposed remuneration guidelines for senior management.

The AGM approved the board’s proposal to be authorized to increase share capital through the issue of new shares, options and/or convertibles.                                                             

The AGM approved the board’s proposal to be authorized to make decisions on the acquisition and/or transferal of own shares.

The AGM approved the board’s proposal for the incentive program 2019/2022.

Complete proposals regarding the AGM’s decisions are available on Boule’s website www.boule.com. 

For further information, please contact:

Peter Ehrenheim, Chairman of the Board Boule Diagnostics AB, phone 0706-67 57 11

Fredrik Dalborg, CEO and Group President Boule Diagnostics AB, phone 070-558 51 05

About Boule Diagnostics AB (publ)

Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com 

The information was submitted for publication, through the agency of the contact person set out above, at 21.00 CET on May 6, 2019.